Related Experiment Video
Updated: Jan 3, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Intravesical Gene Therapy
Vikram M Narayan1, Colin P N Dinney2
1University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1373, Houston, TX 77030, USA. Electronic address: https://twitter.com/VikramNarayan.
Abstract:
Non-muscle-invasive bladder cancer is a challenging disease to treat, with few effective salvage intravesical options available for patients who develop bacillus Calmette-Guerin-unresponsive disease. Although radical cystectomy with pelvic lymphadenectomy remains the gold standard treatment for these patients, there remains an unmet need for other options for those who are unable or unwilling to undergo surgery. To this end, intravesical gene therapy is emerging as a potential alternative with promising early data and ongoing efforts to better understand the mechanisms of action to optimize therapy.
Insights
Non-muscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG) treatment presents challenges. Intravesical gene therapy offers a promising alternative for patients unable or unwilling to undergo radical cystectomy.
Area of Science:
- Oncology
- Urology
- Gene Therapy
Background:
- Non-muscle-invasive bladder cancer (NMIBC) is difficult to treat, especially when unresponsive to bacillus Calmette-Guerin (BCG) therapy.
- Radical cystectomy with pelvic lymphadenectomy is the standard treatment for BCG-unresponsive NMIBC.
- There is a significant need for alternative treatments for patients who cannot or will not undergo surgery.
Purpose of the Study:
- To explore intravesical gene therapy as a potential treatment for BCG-unresponsive NMIBC.
- To highlight the unmet need for salvage options in NMIBC management.
- To discuss the emerging role of gene therapy in bladder cancer treatment.
Main Methods:
- Review of current treatment landscape for NMIBC.
- Exploration of intravesical gene therapy as a novel therapeutic approach.
- Discussion of early data and ongoing research in gene therapy for bladder cancer.
Main Results:
- Intravesical gene therapy shows promise as an alternative to radical cystectomy.
- Early data suggests potential efficacy in treating BCG-unresponsive NMIBC.
- Further research is needed to optimize gene therapy mechanisms and outcomes.
Conclusions:
- Intravesical gene therapy represents a potential breakthrough for managing challenging NMIBC cases.
- This approach addresses the limitations of current salvage options.
- Understanding the mechanisms of action is crucial for advancing gene therapy in bladder cancer treatment.
More Related Videos
05:09Lumbar Intrathecal Injection of Gene Therapy Vectors for Central Nervous System Targeting in Mice and Rats
Published on: May 16, 2025
12:30Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
Published on: August 12, 2014
Related Concept Videos
Gene Therapy
Microorganisms in Medicine and Therapeutics
In-vitro Mutagenesis